Can I Take Reishi Mushroom with Synthroid?

What Is Reishi Mushroom and Why Do Thyroid Patients Use It?

Reishi (Ganoderma lucidum) is a woody fungus used in East Asian medicine for over 2,000 years. Thyroid patients are drawn to it mainly for its reputation as an adaptogen and immune modulator. The mushroom contains three primary bioactive classes: polysaccharides (beta-glucans), triterpenes (ganoderic acids), and proteoglycans.

Why Hypothyroid Patients Seek It Out

Hashimoto's thyroiditis is an autoimmune condition. Because reishi is marketed as an immune "balancer," patients with Hashimoto's sometimes add it hoping to reduce antibody burden or inflammation. A 2015 review in the Journal of Ethnopharmacology documented Ganoderma's broad immunological activity, including modulation of interleukin-2, TNF-alpha, and interferon-gamma pathways [1].

The appeal makes sense on the surface. The clinical evidence in human thyroid disease, however, is limited.

What the Research Actually Shows on Immune Modulation

Animal and in vitro data show that Ganoderma polysaccharides can both stimulate and suppress immune activity depending on dose and model [2]. A 2012 study in PLOS ONE found that Ganoderma lucidum extract significantly enhanced NK-cell cytotoxicity in healthy volunteers (N=34) [3]. Stimulating immune activity in a patient whose immune system is already attacking thyroid tissue is not straightforwardly beneficial.

No randomized controlled trial has measured Ganoderma's effect on TPO antibodies, thyroglobulin antibodies, or TSH levels in humans with Hashimoto's as of the date of this review.

How Could Reishi Interact with Levothyroxine?

The interaction is primarily pharmacodynamic, not pharmacokinetic. That distinction matters.

Pharmacokinetic Interactions: Low Confirmed Risk

Pharmacokinetic interactions with levothyroxine typically occur when a substance binds the drug in the gut, reducing absorption. Calcium carbonate, cholestyramine, and ferrous sulfate are textbook examples [4]. Reishi is not known to chelate or bind levothyroxine in the GI tract. No published study documents reishi reducing levothyroxine bioavailability.

A 30-60 minute separation window between levothyroxine and reishi is still prudent. Levothyroxine absorption is sensitive to many variables, and the American Thyroid Association recommends taking it on an empty stomach, 30-60 minutes before food or other supplements [5].

Pharmacodynamic Interaction 1: Immune Modulation

This is the mechanism with the most biological plausibility in Hashimoto's patients. Levothyroxine replaces the hormone the thyroid can no longer make adequately. It does not suppress the autoimmune attack itself. If reishi further stimulates immune surveillance, the autoimmune load on residual thyroid tissue could theoretically increase, potentially changing the dose of levothyroxine needed over time.

The 2020 American Thyroid Association guidelines on hypothyroidism management note that thyroid function can change with immune-modulating therapies, requiring TSH reassessment [5]. Reishi is not specifically named, but the principle applies.

Pharmacodynamic Interaction 2: Anticoagulant Potentiation

Reishi has measurable antiplatelet activity. A randomized crossover trial (N=33) published in Lipids in Health and Disease found that Ganoderma lucidum extract significantly reduced ADP-induced platelet aggregation compared to placebo (P<0.05) [6]. Levothyroxine itself has a narrow therapeutic index and does not directly affect coagulation. The concern arises when a patient is also on warfarin, aspirin, or other anticoagulants alongside both levothyroxine and reishi.

Hyperthyroid states (from levothyroxine overdose) also increase warfarin sensitivity by accelerating clotting-factor catabolism [7]. A patient who is over-replaced on levothyroxine and also taking reishi plus warfarin faces a stacked bleeding risk. INR monitoring becomes more frequent in that scenario.

What Specific Compounds in Reishi Drive the Interaction?

Ganoderic Acids and CYP Enzymes

Triterpene ganoderic acids have shown CYP3A4 and CYP1A2 inhibitory activity in liver microsome models [8]. Levothyroxine is not primarily metabolized by CYP enzymes (its deiodination is handled by deiodinase enzymes), so direct CYP-mediated drug metabolism changes for levothyroxine are not the primary concern [9]. Patients taking other thyroid-adjacent medications metabolized by CYP3A4, such as carbamazepine or rifampin (which induce levothyroxine clearance), should flag the combination to their clinician.

Beta-Glucan Polysaccharides and Immune Shift

Beta-glucans bind dectin-1 receptors on macrophages and dendritic cells, triggering downstream cytokine release [10]. In autoimmune thyroid disease, dendritic cell activity influences regulatory T-cell (Treg) and effector T-cell (Teff) balance. A 2018 paper in Frontiers in Immunology characterized how Ganoderma polysaccharides shift this balance in murine autoimmune models, though human thyroid-specific data remain absent [11].

Proteoglycans and Platelet Function

The proteoglycan fraction of Ganoderma has been linked to inhibition of thromboxane B2 synthesis, a pathway that normally drives platelet aggregation [12]. This is a separate mechanism from the ganoderic acid pathway, meaning reishi has at least two independent antiplatelet routes. Patients scheduled for surgery should stop reishi at least 10 days before the procedure, consistent with general pre-surgical supplement guidance from the American Society of Anesthesiologists [13].

Clinical Monitoring: What to Track When Taking Both

Managing the reishi-levothyroxine combination, if a patient chooses to proceed, follows a structured approach:

TSH and Free T4 Testing Schedule

• Baseline TSH and Free T4 before starting reishi.
• Repeat at 6-8 weeks after starting reishi, matching the standard re-check interval the American Thyroid Association recommends after any medication or supplement change [5].
• If TSH drifts outside the target range (typically 0.5-2.5 mIU/L for most patients, per current ATA guidance), the levothyroxine dose requires adjustment before attributing it solely to reishi.

A 2021 analysis in Thyroid journal found that adherence variability alone shifts TSH by more than 1.0 mIU/L in approximately 28% of levothyroxine users [14]. So isolating a reishi-specific TSH change requires controlling for dose consistency first.

Coagulation Monitoring

Patients on warfarin should have an INR check within 2 weeks of starting or stopping reishi. A change of 0.3 or more in INR warrants a dose review with the anticoagulation clinician.

Thyroid Antibody Tracking

For Hashimoto's patients specifically, repeat TPO antibody and anti-thyroglobulin antibody levels at 3-6 months can reveal whether immune modulation is shifting the autoimmune burden. This is not standard practice for all hypothyroid patients, but it provides useful data in this context.

Reishi Mushroom Dosing and Product Quality Considerations

Typical Doses in Research

Published studies have used a wide range. A 12-week trial of Ganoderma lucidum extract for immune function used 1.8 g/day of a standardized extract [3]. A study examining platelet function used 1.5 g/day of a polysaccharide-rich extract [6]. Consumer products typically label 500 mg to 3,000 mg per serving, often without standardizing the active polysaccharide or triterpene content.

Adulteration and Label Accuracy

A 2017 investigation by the American Botanical Council found that a proportion of commercial reishi products contained primarily mycelium grown on grain substrate, with substantially lower triterpene content than products made from the fruiting body [15]. The substrate grain can also introduce starch into the supplement, which is not hazardous but changes the pharmacological profile compared to study extracts.

The FDA does not pre-market review dietary supplements for potency or purity [16]. Patients should look for third-party testing marks (USP, NSF International, or Informed Sport) before choosing a product.

What Happens If You Are Already Taking Both?

Do not stop reishi abruptly without telling your prescribing clinician. Abrupt cessation of any immune-modulating supplement before a scheduled TSH test can produce a rebound effect that obscures the true baseline. The practical steps:

1. Schedule a TSH and Free T4 if more than 8 weeks have passed without a check.
2. Review your current levothyroxine dose timing. Confirm you are taking it on an empty stomach, at least 30-60 minutes before food, coffee, or supplements.
3. Bring your reishi product (bottle included) to your next appointment so the clinician can assess dose and formulation.
4. If you are on warfarin, request an INR check within 2 weeks of disclosure.

The Natural Medicines Database rates the reishi-levothyroxine combination as warranting caution, specifically noting the theoretical immune-modulating mechanism and the antiplatelet activity [17]. Caution-level interactions do not mean automatic discontinuation but do require clinician oversight.

Does Reishi Affect Thyroid Function Directly?

Animal Data

A 2009 study in rodents found that high-dose Ganoderma lucidum extract reduced serum T3 and T4 levels in euthyroid animals by approximately 15-20% over 8 weeks, though the mechanism was not clearly established [18]. If this effect translates to humans, a patient replacing thyroid hormone with levothyroxine could see a shift in their T3/T4 ratio without a proportionate TSH change, since exogenous levothyroxine suppresses TSH through a feedback loop independent of direct thyroid gland output.

This animal finding has not been replicated in a controlled human trial. It is a signal, not a conclusion.

Human Data Gaps

A search of ClinicalTrials.gov as of January 2025 returns no completed randomized trials measuring Ganoderma lucidum's effect on thyroid function in humans. This data gap is itself clinically meaningful: absence of evidence of harm is not evidence of absence of harm, particularly for a narrow-therapeutic-index drug like levothyroxine.

Reishi and Specific Levothyroxine Formulations

Patients on Tirosint (levothyroxine in a gel cap formulation) have fewer absorption variables than those on standard tablet formulations, because Tirosint eliminates many excipient interactions [19]. Even so, the pharmacodynamic interaction concerns described above apply regardless of formulation. Switching to Tirosint does not eliminate the need for TSH monitoring when reishi is added.

Patients on combination T3/T4 therapy (levothyroxine plus liothyronine) should be particularly attentive. Liothyronine (Cytomel) has a shorter half-life (about 1 day versus levothyroxine's 6-7 days), so immune-mediated changes in thyroid status can manifest more quickly [20].

What Clinicians Are Saying

The Endocrine Society's 2021 clinical practice guideline on thyroid hormone treatment states: "Clinicians should ask patients about the use of dietary supplements and herbal products, as these may alter thyroid hormone levels or interact with levothyroxine therapy" [21].

A similar position is reflected in the American Thyroid Association's patient FAQ: "Some supplements and foods can interfere with your thyroid medication. Always tell your doctor about any supplements you are taking" [5].

Neither guideline names reishi mushroom by name, because high-quality human trial data do not yet exist to support a product-specific recommendation. The absence of a specific warning is not a clearance.

Risk Stratification: Who Should Be Most Cautious?

Not every levothyroxine patient faces the same level of concern. The highest-risk profiles include:

• Patients with Hashimoto's thyroiditis taking reishi for immune reasons, where immune stimulation may accelerate autoimmune activity.
• Patients also on warfarin, heparin, clopidogrel, or NSAIDs, where reishi's antiplatelet effect stacks with existing bleeding risk.
• Patients with unstable TSH (fluctuating more than 1.0 mIU/L between checks), where any additional variable complicates management.
• Patients planning surgery within 10-14 days, given the antiplatelet mechanism [13].
• Patients on thyroid cancer suppression protocols where TSH must be kept below 0.1 mIU/L; even modest immune shifts could complicate monitoring.

Patients with stable TSH, no anticoagulant use, and no active autoimmune thyroid disease carry a lower (though not zero) interaction risk.